2019
Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension
Shelburne NJ, Parikh KS, Chiswell K, Shaw LK, Sivak J, Arges K, Tomfohr J, Velazquez EJ, Kisslo J, Samad Z, Rajagopal S. Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. The American Journal Of Cardiology 2019, 124: 1298-1304. PMID: 31481176, DOI: 10.1016/j.amjcard.2019.07.026.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntihypertensive AgentsEchocardiographyExercise TestFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedNorth CarolinaPrognosisPulmonary Arterial HypertensionRetrospective StudiesSeverity of Illness IndexStroke VolumeSurvival RateVentricular Function, RightYoung AdultConceptsTricuspid annular plane systolic excursionPulmonary arterial hypertensionRV global longitudinal strainRV systolic pressureRight ventricular functionGlobal longitudinal strainArterial hypertensionSystolic pressureVentricular functionSevere pulmonary arterial hypertensionAnnular plane systolic excursionLongitudinal strainPAH-specific therapyManagement of patientsRight atrial areaMid-RVPAH therapyCause mortalityEchocardiographic parametersClinical responseEchocardiographic variablesSystolic excursionWalk distanceEchocardiographic assessmentAtrial area
2018
Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes
Bishawi M, Zanotti G, Shaw L, MacKenzie M, Castleberry A, Bartels K, Schroder J, Velazquez E, Swaminathan M, Rogers J, Milano C. Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes. The Annals Of Thoracic Surgery 2018, 107: 1348-1355. PMID: 30529215, PMCID: PMC7256852, DOI: 10.1016/j.athoracsur.2018.10.065.Peer-Reviewed Original ResearchConceptsSignificant tricuspid valve regurgitationTricuspid valve regurgitationLong-term outcomesHeart transplantationCardiopulmonary bypassTR gradeValve regurgitationSurgical repairValve repairCommon findingOrthotropic heart transplantationPostoperative plasma creatininePulmonary vascular resistanceTricuspid valve repairEarly surgical repairEarly morbidityPostoperative stayCardiac transplantationMultiorgan transplantsVascular resistanceTransplant databaseHeart transplantAdjusted survivalPlasma creatinineTransplantLong-term outcomes of mitral regurgitation by type and severity
Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander JH, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal 2018, 203: 39-48. PMID: 30015067, DOI: 10.1016/j.ahj.2018.05.001.Peer-Reviewed Original ResearchConceptsMR severityCause deathIschemic MRSurvival rateCause death riskCoronary artery diseaseLong-term outcomesAbsolute mortality ratesQualifying patientsArtery diseaseEchocardiography studyMitral regurgitationVentricular sizeIndeterminate causeBaseline severityDeath riskSevere MREchocardiography laboratoryHigh riskMortality rateClinical settingPatientsValve morphologySeverityMyxomatousRationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal 2018, 198: 145-151. PMID: 29653636, DOI: 10.1016/j.ahj.2018.01.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAminobutyratesBiphenyl CompoundsCardiac Output, LowCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsDrug Delivery SystemsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPatient SafetyPeptide FragmentsPrognosisProspective StudiesRisk AssessmentSeverity of Illness IndexSurvival RateTetrazolesTreatment OutcomeValsartanConceptsAcute decompensated heart failureSacubitril/valsartanB-type natriuretic peptideDecompensated heart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptideEjection fractionHeart failureHospital initiationNatriuretic peptideEnd pointClass angiotensin receptor neprilysin inhibitorAngiotensin receptor neprilysin inhibitorPg/Primary efficacy end pointAmbulatory HF patientsExploratory end pointsPIONEER-HF trialEfficacy end pointReduced ejection fractionSafety end pointOpen-label treatmentIncidence of angioedemaYears of agePIONEER-HF
2017
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF
Pokorney SD, Al‐Khatib S, Sun J, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF. European Journal Of Heart Failure 2017, 20: 525-532. PMID: 29266564, DOI: 10.1002/ejhf.1078.Peer-Reviewed Original ResearchConceptsSudden cardiac deathVT/VFHeart failure hospital admissionsAcute HFCardiac deathHospital admissionVentricular tachycardia/ventricular fibrillationDecompensated Heart Failure (ASCEND-HF) trialChronic obstructive pulmonary diseaseVT/VF eventsEvent ratesComposite event rateMeier event ratesHeart Failure TrialCause mortality ratesDay of admissionObstructive pulmonary diseaseLonger QRS durationCause mortalityBaseline characteristicsComposite endpointEjection fractionPulmonary diseaseASCEND-HFFailure TrialComparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease)
Banks A, Broderick S, Chiswell K, Shaw L, Devore A, Fiuzat M, O'Connor C, Felker GM, Velazquez E, Mentz R. Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). The American Journal Of Cardiology 2017, 119: 1703-1709. PMID: 28395884, DOI: 10.1016/j.amjcard.2017.02.053.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseAngina pectorisDiabetes mellitusDM statusCause mortalityMultivariable Cox regressionOutcomes of patientsDifferent prognostic implicationsSeverity of diseaseAP statusCV hospitalizationClinical characteristicsArtery diseaseCoronary angiographyDM patientsClinical outcomesCox regressionPrognostic implicationsPrognostic utilityRevascularizationSimilar riskPatientsRisk adjustmentMortalityPectoris
2016
Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction
Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA, Al-Khatib SM, Velazquez EJ, Peterson ED, Wang TY. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation 2016, 135: 38-47. PMID: 27881561, DOI: 10.1161/circulationaha.116.022359.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDefibrillators, ImplantableFemaleHeart VentriclesHumansMagnetic Resonance ImagingMaleMedicareMyocardial InfarctionMyocardial RevascularizationProportional Hazards ModelsRegistriesRetrospective StudiesStroke VolumeSurvival RateTomography, X-Ray ComputedUltrasonographyUnited StatesConceptsLow ejection fractionEjection fractionICD implantationMyocardial infarctionMI admissionsRevascularization statusImplantable cardioverter-defibrillator (ICD) useACTION Registry-GWTGICD implantation ratesMultivariable Cox modelPost-MI patientsYears of ageImplantation rateCardiac functionMedicare patientsCox modelPatientsAdmissionHigher likelihoodInfarctionImplantationAssociationYearsStatusICDClinical and echocardiographic predictors of mortality in acute pulmonary embolism
Dahhan T, Siddiqui I, Tapson VF, Velazquez EJ, Sun S, Davenport CA, Samad Z, Rajagopal S. Clinical and echocardiographic predictors of mortality in acute pulmonary embolism. Cardiovascular Ultrasound 2016, 14: 44. PMID: 27793158, PMCID: PMC5086059, DOI: 10.1186/s12947-016-0087-y.Peer-Reviewed Original ResearchConceptsAcute pulmonary embolismChronic obstructive pulmonary diseaseBody mass indexTricuspid annular plane systolic excursionPulmonary artery acceleration timePulmonary embolismActive malignancyEjection fractionClinical parametersMass indexNYHA class III symptomsRV myocardial performance indexAnnular plane systolic excursionLeft ventricular ejection fractionMedian body mass indexClass III symptomsFraction area changeRV Tei indexSpeckle-tracking strainOutcomes of patientsAbsence of hypertensionTroponin T levelsMyocardial performance indexObstructive pulmonary diseaseSystolic blood pressureTen-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2016, 134: 1314-1324. PMID: 27573034, PMCID: PMC5089908, DOI: 10.1161/circulationaha.116.024800.Peer-Reviewed Original ResearchConceptsCoronary artery bypassCause mortalityMedical therapyCardiovascular mortalityYounger patientsEjection fractionHeart failureCABG groupArtery bypassOlder patientsCardiovascular hospitalizationBenefit of CABGEfficacy of CABGCardiopulmonary bypass timeReduced ejection fractionVentricular systolic dysfunctionBaseline ejection fractionCoronary artery diseaseEffect of CABGTen-year outcomesConsistent beneficial effectsMore comorbiditiesSTICH trialBypass timeCardiovascular deathCardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy
Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. Journal Of Clinical Hypertension 2016, 18: 299-307. PMID: 27060568, PMCID: PMC8032014, DOI: 10.1111/jch.12816.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHypertensionIncidenceMaleMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsStrokeSurvival RateSystoleTreatment OutcomeUnited StatesConceptsSystolic blood pressureNondiabetic cohortCardiovascular outcomesPrimary endpointBlood pressurePrimary endpoint event rateTreatment systolic blood pressureEvent ratesAvoiding Cardiovascular EventsBlood pressure targetsDifferent SBP targetsFurther SBP reductionSystolic Hypertension (ACCOMPLISH) trialAdverse renal eventsComposite primary endpointTotal stroke ratesCV protectionNondiabetic patientsRenal considerationsRenal eventsSBP categoriesSBP reductionCardiovascular eventsHypertension trialsPressure targets
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureImportance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH
Jolicœur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, Stewart R, Jhund PS, Desvigne-Nickens P, Panza JA, Bonow RO, Sun B, San TR, Al-Khalidi HR, Rouleau JL, Velazquez EJ, Cleland JGF. Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH. Journal Of The American College Of Cardiology 2015, 66: 2092-2100. PMID: 26541919, PMCID: PMC4655599, DOI: 10.1016/j.jacc.2015.08.882.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseLV systolic dysfunctionGreater survival benefitMedical therapySystolic dysfunctionCause mortalitySurvival benefitWorse prognosisCoronary artery bypass graft surgeryLeft ventricular systolic dysfunctionArtery bypass graft surgeryLong-term clinical outcomesGreater prognostic benefitBypass graft surgeryVentricular systolic dysfunctionEffect of CABGMultivariable CoxSTICH trialGraft surgeryPrognostic benefitArtery diseaseCoronary diseaseEjection fractionHeart failureClinical outcomesComparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiureticsThe MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison
Velazquez EJ, Samad Z, Al-Khalidi HR, Sangli C, Grayburn PA, Massaro JM, Stevens SR, Feldman TE, Krucoff MW. The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison. American Heart Journal 2015, 170: 1050-1059.e3. PMID: 26542516, DOI: 10.1016/j.ahj.2015.08.004.Peer-Reviewed Original ResearchConceptsMitraClip patientsCox proportional hazards modelPropensity-matched comparisonSevere MR patientsHigh surgical riskHigh-risk patientsNon-surgical treatmentKaplan-Meier estimatesMitral regurgitation patientsProportional hazards modelSurvival benefitMedical therapySurgical riskMitral regurgitationRelative riskBaseline differencesHigh riskMR patientsHazards modelMitraClipPatientsFurther adjustmentLaboratory databasePropensity scorePatient matchingGenetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)
Bloomfield GS, Temu TM, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Shen C, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS. Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). American Heart Journal 2015, 170: 455-464.e5. PMID: 26385028, PMCID: PMC4575772, DOI: 10.1016/j.ahj.2015.06.008.Peer-Reviewed Original ResearchConceptsValvular atrial fibrillationNonvalvular atrial fibrillationValvular heart diseaseAtrial fibrillationHeart diseaseCurrent tobacco smokingHistory of strokeCase-control studyGroup morbidityGenetic associationTobacco smokingSaharan AfricaMean ageAfrican patientsCardiovascular diseaseClinical phenotypingFibrillationPrimary analysisPatientsControl populationGenetic testingMorbidityDiseaseGenetic mutationsMost participants
2013
Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction
Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. Journal Of The American College Of Cardiology 2013, 61: 2365-2373. PMID: 23563128, DOI: 10.1016/j.jacc.2013.02.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedCause of DeathCohort StudiesConfidence IntervalsEchocardiography, DopplerFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentSeverity of Illness IndexStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsGlobal longitudinal strainHeart failure hospitalizationVentricular ejection fractionAcute myocardial infarctionMyocardial infarctionFailure hospitalizationSecondary endpointsEjection fractionHigh-risk myocardial infarctionVentricular global longitudinal strainLeft ventricular ejection fractionLongitudinal strainHeart failure admissionsPrimary composite endpointCox regression analysisHigh-risk subjectsVentricular longitudinal strainImportant prognostic informationSignificant prognostic valueAssessment of GLSParticular clinical relevanceCardiovascular deathCause mortalityPrimary endpointCardiac death
2012
Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial
Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, Jain AR, Chua Y, Daly R, Senni M, Mokrzycki K, Menicanti L, Oh JK, Michler R, Wróbel K, Lamy A, Velazquez EJ, Lee KL, Jones RH. Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial. Circulation 2012, 125: 2639-2648. PMID: 22553307, PMCID: PMC3776601, DOI: 10.1161/circulationaha.111.072256.Peer-Reviewed Original ResearchConceptsSevere mitral regurgitationMild mitral regurgitationMitral regurgitationMitral valve repairTrace mitral regurgitationMitral surgeryMedical therapyValve repairIschemic Heart Failure (STICH) trialCoronary artery bypassHeart Failure TrialPrimary end pointLeft ventricular dysfunctionCoronary artery diseaseModerate mitral regurgitationBaseline prognostic variablesIschemic mitral regurgitationArtery bypassRandomized patientsVentricular dysfunctionHazard ratioArtery diseaseEjection fractionMedical armSurgical treatment
2010
STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment
Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL. STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment. Journal Of The American College Of Cardiology 2010, 56: 490-498. PMID: 20670760, PMCID: PMC3259709, DOI: 10.1016/j.jacc.2009.11.102.Peer-Reviewed Original ResearchConceptsLow-risk patientsSTICH trialRAR groupBaseline characteristicsCardiac surgeryIschemic cardiomyopathyHigh-risk patientsNumber of patientsCountry of enrollmentSTICH patientsDuke DatabankRandomization groupTrial enrollmentCardiovascular diseaseRisk differencePatientsClinical decisionTrialsSurgeryCardiomyopathyRiskBroader populationEnrollment performanceDeathThirty-second
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2007
Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings
Bourque JM, Velazquez EJ, Tuttle RH, Shaw LK, O’Connor C, Borges-Neto S. Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. Journal Of Nuclear Cardiology 2007, 14: 165-173. PMID: 17386378, DOI: 10.1016/j.nuclcard.2006.11.011.Peer-Reviewed Original ResearchConceptsMortality riskEjection fractionPrognostic informationHigher long-term mortality ratesLong-term mortality ratesPerfusion single-photon emissionVentricular ejection fractionIschemic heart diseaseLong-term outcomesProportional hazard modelingLong-term survivalSingle photon emissionCardiac catheterizationNormal LVEFRisk stratificationPerfusion findingsPatient prognosticationHeart diseaseRest scoreLVEFMyocardial perfusionMortality ratePerfusion studiesHazard modelingSignificant predictors